$SELB News
Last published 2y ago
- 2y agoRNACSELBCartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for AutoimmunityGlobeNewswireTopline data from Phase 2b study of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024 Positive 12-month follow-up data from Phase
- 2y agoRNACSELBCartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia GravisGlobeNewswireDurable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up period without need for lymphodepleting chemotherapy
- 2y agoSELBSelecta Biosciences Announces Merger with Cartesian TherapeuticsGlobeNewswire– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian's wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for
- 3y agoSELBSelecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner SobiGlobeNewswireWATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for
- 3y agoSELBSelecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 EconomicsGlobeNewswire– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further
- 3y agoSELBSelecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of RheumatologyGlobeNewswire- Phase 3 DISSOLVE I and DISSOLVE II studies both met their primary efficacy endpoints, with SEL-212-treated patients demonstrating statistically significant higher response rates compared to placebo - - SEL-212
- 3y agoSELBSelecta Biosciences, Inc. (SELB) Q1 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoSELBSelecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswire- Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023 - - Reported
- 3y agoSELBSelecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business UpdateGlobeNewswireWATERTOWN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for
- 3y agoDNLIEVLOFHTXIMPL+6Cellarity Strengthens Executive Leadership TeamBusiness WireCellarity, a life sciences company founded by Flagship
- 3y agoSELBPhase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA - NCT05778877ClinicalTrials.govSafety and tolerability of SEL-302, PD Activity of SEL-302, Assess the change in Neutralizing antibody (Nab) titers for MMA-101 with treatment of SEL-110, (and 5 more...)
- 3y agoSELBPhase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum ABPR Newswire--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II --In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE I and 48% in
- 3y agoSELBPhase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary EndpointGlobeNewswire--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II--In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE I and 48% in
- 3y agoSELBSelecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewswire- Topline data for Phase 3 DISSOLVE I & II clinical trials of SEL-212 in chronic refractory gout remains on track for Q1 2023 - - Continue to enroll patients in ReiMMAgine, the Phase 1/2 clinical trial of SEL-302
- 3y agoSELBSelecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business UpdateGlobeNewswireWATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for
- 3y agoSELBSelecta Biosciences to Participate at the SVB Securities Global Biopharma ConferenceGlobeNewswireWATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for
- 3y agoSELBSelecta Biosciences Provides Business Update and Outlook for 2023GlobeNewswire- Expected topline data for Phase 3 DISSOLVE I & II programs of SEL-212 in chronic refractory gout in Q1 2023 - - To receive $10 million upfront for the execution of a license agreement for Xork, the Company's
- 3y agoALPMYSELBTYO:4503Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG ProteasePR NewswireNext-generation IgG protease candidate Xork to be licensed for development with AT845, an investigational Astellas Gene Therapies' product, for the treatment of Pompe Disease Selecta to receive a $10M upfront
- 3y agoSELBSelecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy ProgramGlobeNewswire– IgA protease candidate in combination with ImmTOR further enhances pipeline – – Novel mechanism of action of IgA protease has the potential to address the underlying kidney pathophysiology of IgA nephropathy –
- 3y agoSELBSelecta Biosciences Announces Appointment of Blaine Davis as Chief Financial OfficerGlobeNewswireWATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for
- 4y agoSELBSelecta Biosciences to Participate at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology DayGlobeNewswireWATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop
- 4y agoSELBSelecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswire– DISSOLVE I & II studies of SEL-212 in Chronic Refractory Gout remain on track for joint topline data readout in Q1 2023 – – SEL-302, Selecta's wholly owned gene therapy in combination with ImmTOR for the
- 4y agoSELBSelecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Business UpdateGlobeNewswireWATERTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop
- 4y agoSELBSelecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) ConferenceGlobeNewswireWATERTOWN, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop
- 4y agoSELBSelecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell InteractionsGlobeNewswireWATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune
- 4y agoSELBSelecta Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies
- 4y agoSELBSelecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireWATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies
- 4y agoSELBSelecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswire– Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi); DISSOLVE I & II studies remain on track for joint topline data readout in Q1 2023 – – Sarepta extends O
- 4y agoSELBSelecta Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies
- 4y agoSELBSelecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business UpdateGlobeNewswireWATERTOWN, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies
- 4y agoSELBSelecta Biosciences to Participate at the Guggenheim I&I Spotlight Series – Treg-based Therapies ConferenceGlobeNewswireWATERTOWN, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies
- 4y agoSELBSURFSurface Oncology Appoints Carsten Brunn to Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D.,
- 4y agoSELBSRPTSelecta Biosciences Announces Partnership Advancements and Clinical Trial UpdatesGlobeNewswire-Sarepta extends Research License and Option Agreement for ImmTOR® in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies- -Selecta to receive a $2 million payment from Sarepta extending their option periods under the agreement t
- 4y agoSELBSelecta Biosciences to Participate at the H.C. Wainwright Global Investment ConferenceGlobeNewswireWATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies a
- 4y agoSELBSelecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswire– Phase 1 trial of SEL-302 remains on track to initiate in the second half of 2022 – – DISSOLVE I & II studies on track for completion in Q4 2022 with joint topline readout in Q1 2023 – – Completed underwritten offering, raising approxima
- 4y agoSELBSelecta Biosciences Announces Six Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)GlobeNewswireWATERTOWN, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, power gene therapies and
- 4y agoSELBSelecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business UpdateGlobeNewswireWATERTOWN, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune respo
- 4y agoSELBSelecta Biosciences Announces $38.7 Million Underwritten OfferingGlobeNewswireWATERTOWN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB) ("Selecta" or the "Company"), a biotechnology company focused on developing tolerogenic therapies to mitigate unwanted immune responses, today announced that i
- 4y agoSELBSelecta Biosciences to Participate at the 21st Annual Needham Virtual Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune respo
- 4y agoSELBSelecta Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewswire– U.S. Food and Drug Administration ("FDA") removed clinical hold on SEL-302 for the treatment of patients with methylmalonic acidemia ("MMA")- -Observed the synergy of ImmTOR in combination with engineered Treg-selective IL-2 to expand antigen-
- 4y agoSELBSelecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2021 Financial Results and Provide Business UpdateGlobeNewswireWATERTOWN, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated, precision immune tolerance platform, ImmTOR®, to develop tolerogenic therapies that selectively
- 4y agoSELBSelecta Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune respo
- 4y agoDNASELBSelecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy CapsidsGlobeNewswireWATERTOWN, Mass. and BOSTON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted i
- 4y agoDNASELBSelecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy CapsidsPR NewswireWATERTOWN, Mass. and BOSTON, Jan. 10, 2022 /PRNewswire/ -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immu
- 4y agoSELBSelecta Biosciences to Participate at the 2022 H.C. Wainwright BioConnect ConferenceGlobeNewswireWATERTOWN, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune respo
- 4y agoSELBSelecta Biosciences to Participate at the LifeSci Partners 11th Annual Corporate Access EventGlobeNewswireWATERTOWN, Mass., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune respo
- 4y agoCHRSIBRXITCISEAC+1Thinking about buying stock in Intra-Cellular Therapies, Selecta Biosciences, Coherus Biosciences, ImmunityBio, or SeaChange International?PR NewswireNEW YORK, Dec. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ITCI, SELB, CHRS, IBRX, and SEAC.
- 4y agoAGLEALZNGRTXSELB+1Thinking about buying stock in Galera Therapeutics, Terminix Global, Aeglea Bio Therapeutics, Alzamend Neuro, or Selecta Biosciences?PR NewswireNEW YORK, Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRTX, TMX, AGLE, ALZN, and SELB.
- 4y agoBIOVFSELBSobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chronic refractory goutPR NewswireSTOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ:SELB), today announced the completion of enrolment for DISSOLVE I, the first of two clinical studies of the phase 3 DIS
- 4y agoSELBSelecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating SEL-212 for Chronic Refractory GoutGlobeNewswire-DISSOLVE program on track with 12-month study fully enrolled--DISSOLVE II on track for full enrollment in early 2022--Top-line data from Phase 3 DISSOLVE program expected in H2 2022- WATERTOWN, Mass. and STOCKHOLM, Sweden, Dec. 01, 2021 (GLOBE NEWS